Navigation Links
HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
Date:4/25/2011

SAN DIEGO, April 25, 2011 /PRNewswire/ -- HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that clinical investigators have enrolled the first patient in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease. The study, which is being conducted by investigators in clinical sites in the US, Canada, Jamaica, Egypt and Lebanon, is expected to enroll approximately 50 patients. The primary objective is safety and tolerability of HQK-1001. There are several secondary objectives including an increase in fetal hemoglobin production. HemaQuest expects interim results from the study in late 2011 and final results in the first quarter of 2012.

"Based on the promising results from our prior Phase 2 clinical studies, we are excited to initiate this clinical study testing higher dose levels and longer duration of therapy to more fully characterize the therapeutic potential of HQK-1001 in sickle cell disease," said HemaQuest Chief Medical Officer Richard G. Ghalie, MD. "This is an important next step toward potentially making HQK-1001 available as a treatment for this devastating disease in underserved populations around the world."

ABOUT HQK-1001 HQK-1001 belongs to a class of compounds originally discovered at Boston University School of Medicine. These compounds, designated as Short Chain Fatty Acid Derivatives (SCFADs), have been shown to stimulate fetal hemoglobin expression and red blood cell production in the laboratory and in small clinical trials in patients with hemoglobin disorders, including sickle cell disease and beta thalassemia.  Increased fetal hemoglobin production in red blood cells has been shown to reduce the frequency of pain crises and hospitalizations  of patients with sickle cell disease  HQK-1001 is an orally administered SCFAD, which has shown an excellent safety profile and biologic effects on fetal hemoglobin induction and red blood cell production in the laboratory, relevant animal models, and in clinical trials carried out in healthy human subjects as well as patients with sickle cell disease and beta thalassemia. The compound has received Orphan Drug Designation in the United States and Europe for both sickle cell disease and beta thalassemia.

ABOUT SICKLE CELL DISEASE Sickle cell disease is a genetic blood disorder that affects approximately 110,000 patients in the U.S. and Europe and 250,000 in the Middle East. Sickle cell disease is characterized by production of an abnormal beta hemoglobin chain of adult hemoglobin, which results in distorted, rigid sickle red blood cells, which block blood vessels, causing lack of oxygen to tissues, acute episodes of pain (pain crises), lung injury (acute chest syndrome), and strokes. Infections are common, and chronic damage occurs in many organs, including the spleen, bones, kidneys, lungs, brain, and eyes. The sole drug which is approved to treat the disease is a cancer chemotherapy drug, hydroxyurea.  The lifespan of sickle cell patients is markedly reduced.

ABOUT HEMAQUEST PHARMACEUTICALS, INC.HemaQuest Pharmaceuticals (www.HemaQuest.com), established in late 2007, is a San Diego and Seattle-based biopharmaceutical company focused on developing small molecule therapeutics based on its proprietary SCFAD technologies to treat hemoglobin diseases. HemaQuest is also developing a proprietary multi-drug therapeutic approach for treating viral-associated malignancies, with a primary focus on Epstein-Barr virus associated lymphomas. The Company's investors include De Novo Ventures, Forward Ventures, Lilly Ventures, Aberdare Ventures and Latterell Venture Partners.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.CONTACTS:

Jerome Lyons

Tamara A. SeymourOffice Manager

Chief Financial OfficerT: 206.826.9900

T: 858.356.5582jlyons@hemaquest.com

tseymour@hemaquest.com
'/>"/>

SOURCE HemaQuest Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
2. HemaQuest Announces Appointment of New Executive Management Team; Company Establishes Headquarters in San Diego
3. HemaQuest Pharmaceuticals, Inc. Presents Promising Clinical Results at 52nd Annual Meeting of the American Society of Hematology (ASH)
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... MELVILLE, N.Y. , Feb. 5, 2016  Henry ... of health care products and services to office-based dental, ... has entered into an agreement to acquire a majority ... dental supplies and equipment in Brazil ... Headquartered in Blumenau, Brazil, Dental Cremer is the dental ...
(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... the addition of the "Global Obstetrics ... company profile to their offering. ... addition of the "Global Obstetrics Partnering ... company profile to their offering. --> ...
(Date:2/4/2016)... Feb. 4, 2016  The Senior Care Pharmacy ... Reform Committee Chairman Jason Chaffetz (R-UT) ... today,s hearing , "Developments in the Prescription ... and growing questions about abusive pharmacy benefit manager ... (R-UT) and Ranking Member Elijah Cummings (D-MD) are ...
Breaking Medicine Technology:
(Date:2/6/2016)... , ... February 06, 2016 , ... ... of eating disorder treatment helps to reduce the frequency and level of relapse. ... Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of ...
(Date:2/5/2016)... Bethpage, NY (PRWEB) , ... February 05, 2016 , ... ... florist-quality long-stem roses in a variety of colors, assortments and packaging. This staple for ... at any King Kullen location. , For Valentine’s Day, not only are long-stem ...
(Date:2/5/2016)... & Salt Lake City, UT (PRWEB) , ... February 05, 2016 ... ... of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi ... New Really Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food ...
(Date:2/5/2016)... , ... February 05, 2016 , ... The event is ... Day Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 ... owner of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... the addition of micro-needling services in their Napa Valley office. The technique utilizes ... Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a ...
Breaking Medicine News(10 mins):